The Retirement of the "Pharmaceutical Industry Godfather": Behind Zhu Baoguo's Retirement, the "Midlife Crises" of Jiankangyuan and Livzon, and the Need for Transformation
Hello everyone, I'm your financial observer. Today, we're talking about a well-known figure in the pharmaceutical industry—Zhu Baoguo.
If you were born in the 1980s or 1990s, you've probably heard the advertisement for "Taitai Oral Liquid," with the slogan "Taitai Oral Liquid, good for nourishing blood and energy." Its founder, Zhu Baoguo, officially announced his retirement on September 11th, handing over the reins of two listed companies he had led for 25 years: Jiankangyuan and Livzon Group.
This is not just the retirement of a businessman; it's also the end of an era. Against the backdrop of national centralized procurement and the transformation towards innovative drugs, this power transition is filled with drama and urgency. Let me break down this event into five key points to help you understand the implications.
---
1. From "Chemical Technician" to "Health Product King": Zhu Baoguo's Entrepreneurial Legend
To understand Zhu Baoguo's significance, we need to look at how he started his journey.
Zhu Baoguo didn't come from a medical background; he was originally a chemical technician. In the 1990s, when China's health product industry was booming, he recognized the need for women's health products and launched Taitai Oral Liquid in 1993. This product not only made him a fortune but also earned him fame alongside Shi Yuzhu (the founder of Brain White Gold), earning him the title of "Health Product King."
What sets Zhu Baoguo apart is that he didn't stop at selling health products. He used the profits to enter the more challenging pharmaceutical industry:
- 2001: His company, Taitai Pharmaceutical, went public.
- 2002: He acquired Livzon Pharmaceutical Group.
- 2003: Taitai Pharmaceutical was renamed Jiankangyuan.
By this time, Zhu Baoguo controlled two powerful companies: Jiankangyuan (the parent company, focusing on biologics and active pharmaceutical ingredients) and Livzon Group (the subsidiary, specializing in chemical drugs). This dual-listed structure gave him significant influence in the capital market and established his status as a key figure in China's pharmaceutical industry.
In simple terms: Zhu Baoguo was like a shrewd real estate developer who first made quick money by selling houses (health products) and then moved on to building luxury offices and complexes (pharmaceutical products), significantly increasing the company's value.
---
2. "Jiankangyuan in One Hand, Livzon in the Other": The Two Faces of One Company
Many readers may wonder about the relationship between Jiankangyuan and Livzon Group. Why did both companies need new chairmen after Zhu Baoguo's retirement?
Jiankangyuan is the "parent company," while Livzon Group is the "son company," but Livzon is much larger and more well-known:
- Jiankangyuan (600380.SH): The controlling shareholder with a diverse range of businesses, including chemical drugs, biologics, and health products.
- Livzon Group (000513.SZ / 01513.HK): A key subsidiary of Jiankangyuan, known for its strength in chemical pharmaceuticals and consistently ranking among the top 100 Chinese pharmaceutical companies.
Interesting statistics:
- 2025 Performance: Jiankangyuan had revenue of 15.2 billion yuan and a net profit of 1.336 billion yuan; Livzon Group had revenue of 12 billion yuan and a net profit of 2.023 billion yuan.
- Market Value: As of September 2026, Livzon Group's market value was 23.6 billion yuan, while Jiankangyuan's was 16.9 billion yuan.
In simple terms: Jiankangyuan is like the father with multiple businesses, but Livzon is the main source of profit.
In simple terms: It's like a family business where the father (Jiankangyuan) owns several businesses, but the son (Livzon) is the one that generates the majority of the income. Now that the father has retired, the management has been handed over to new professional managers.
---
3. Why Retire Now? Because of the "Painful Transition"
Zhu Baoguo chose this moment to retire, not due to health issues, but because the industry is undergoing a significant transformation:
- National Centralized Procurement: The government has implemented centralized procurement to lower drug prices, leading to a sharp decline in the prices of traditional generic drugs.
- Performance Decline: Both Jiankangyuan and Livzon Group saw significant revenue and profit reductions in the first half of 2026.
Why such a sharp decline?
- Price Drops: Livzon's popular drugs, such as esomeprazole sodium and leuprorelin, saw reduced sales due to price cuts and centralized procurement.
- Industry Challenges: The raw materials industry is in a downturn, and the traditional Chinese medicine and diagnostic reagent sectors are affected by seasonal fluctuations.
In simple terms: While Zhu Baoguo's leadership helped the company thrive with its existing products, the new leadership must adapt to these challenges and focus on innovative drugs.
---
4. Who Are the Successors? Two Young, Internally Promoted Managers
Zhu Baoguo didn't choose external experts or his own children; instead, he appointed young, internally trained managers:
- New Chairman of Jiankangyuan: Liu Daping (39 years old), with a background in production, who rose from the workshop to vice president and then president.
- New Chairman of Livzon Group: Lin Nanqi (44 years old), also from within the company, with experience in production, management, and research and development.
Why these choices?
- Stability: They are familiar with the company culture and processes, reducing transition uncertainties.
- Youthfulness: They are in their prime, energized, and well-equipped for the competitive landscape of innovative drugs.
- Professionalism: Their experience in production is crucial for the company's transformation.
In simple terms: Zhu Baoguo trusted experienced managers, not just because of their age, but because of their expertise and dedication.
---
5. The Future Challenge: The Transition from Generics to Innovatives
Zhu Baoguo's legacy is a solid foundation for the company's future. The new leaders face a tough task:
- Surviving the Centralized Procurement: The management expects 2026 to be the most challenging year, with hopes of stabilization in 2027.
- Investing in Innovation: Livzon is focusing on launching new drugs; success depends on their ability to sell these products effectively and replace outdated ones.
- International Expansion: The company must expand overseas, which requires expertise in compliance, certification, and branding.
In simple terms: The new leaders must transform the company from a traditional pharmaceutical player to a global player.
Zhu Baoguo's retirement marks the end of an era of health product and generic drug dominance. His successors' challenge is to shift from selling cheap drugs to developing innovative, unique medicines. There's no fixed formula for success; the market will determine the outcome.
For investors and the public, following the progress of these two companies is key to understanding China's pharmaceutical industry's transition from being large to becoming strong. Zhu Baoguo's legacy is a solid foundation for the industry's future growth. The new chapter is just beginning.